0 likes | 20 Views
Rising R&D expenditures and diminishing pharmaceutical company revenues are driving the industry, as are increased regulatory scrutiny, expanding need for market access, RWE, HEOR, pricing and reimbursement, regulatory & compliance services, and R&D problems connected to complicated treatments.
E N D